MNKD logo

MNKD MannKind Corporation

NASDAQ Global Market · Biotechnology · Healthcare

$3.85
-0.10 (-2.53%)

MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind a…

Market Cap: $1.24Bwww.mannkindcorp.com

Price

No data yet.

Social Signal Score

45
5d
40
2 mentions
—
30d
47
6 mentions
—
60d
46
10 mentions
—
90d
49
14 mentions
—
news: 14

Analyst Ratings

21 analysts
Buyconsensus
Strong Buy 0Buy 11Hold 3Sell 7Strong Sell 0
Avg price target$11+185.7%
Low $10Median $10High $13
Current Consensus

Revenue

$101.87M+721.27%
$2.04M$38.68M$75.32M$111.95M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$0.17
$0.16–$0.19
4 analysts
FY2026
$-0.17-200% YoY
$-0.18–$-0.16
6 analysts
FY2027
$0.05
$0.01–$0.11
6 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Michael E. Castagna
Sector
Healthcare
Industry
Biotechnology
Employees
592
Beta
1.09
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
-4.62
www.mannkindcorp.com